Article
With a potential $458M per target payday, Aligos teams up with Merck hoping to reverse biotech's re
Rating:
0.0
Views:
109
Likes:
1
Library:
1
Just a few months after going public with a $150 million IPO, Aligos Therapeutics $ALGS is aiming to further capitalize on its momentum with a new NASH deal. The biotech has teamed up with Merck to try to develop oligonucleotide therapies for the disease, a slate that could be worth
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value